<DOC>
	<DOCNO>NCT02494596</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics combination rhuMab 2C4 ( Perjeta ) capecitabine ( Xeloda ) participant advance solid tumor progress standard therapy , standard therapy available . Participants enrol evaluated dose-limiting toxicity ( DLTs ) escalating-dose cohort order determine maximum tolerate dose ( MTD ) .</brief_summary>
	<brief_title>A Phase Ib , Open-label , Multicenter Study Safety PK Combination rhuMAb2c4 ( Omnitarg ) , Recombinant Humanized Antibody HER2 , Capecitabine ( Xeloda ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Adults least 18 year age Easter Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Locally advance metastatic solid tumor least 1 measurable lesion , progress during/after standard therapy Human epidermal growth factor receptor 2 ( HER2 ) negative among participant breast cancer Negative pregnancy test use adequate contraceptive method among woman childbearing potential Adequate hematologic , hepatic , renal function Clinical evidence central nervous system ( CNS ) metastases Prior chemotherapy , radiotherapy , immunotherapy within 4 week , hormone therapy within 2 week study Day 1 History palmar plantar syndrome Grade 2 worse , unresolved residual chemotherapy effect Prior HER2active agent , continuous intravenous ( IV ) 5fluorouracil , capecitabine , fluoropyrimidine Any investigational agent within 28 day study start Prior cumulative doxorubicin dose great ( &gt; ) 360 mg/m^2 equivalent Significant cardiovascular disease Active/uncontrolled concurrent illness infection Major surgery trauma within 4 week study Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>